De novo patients with high-volume metastatic hormone-sensitive prostate cancer can benefit from the addition of docetaxel to triplet therapy: Network-analysis and systematic review

Saved in:
Bibliographic Details
Published in中华医学杂志英文版 Vol. 138; no. 2; pp. 231 - 233
Main Authors Guo Hanxu, Jin Chengqi, Ding Li, Xie Jun, Xu Jing, Wang Ruiliang, Wang Hong, Guo Changcheng, Zhang Jiansheng, Peng Bo, Yao Xudong, Yuan Jing, Yang Bin
Format Journal Article
LanguageChinese
Published Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai 200072, China%Department of Urology, Urologic Cancer Institute, Tongji University School of Medicine, Shanghai 200072, China%Department of Urology, School of Medicine, Anhui University of Science and Technology, Huainan, Anhui 232001, China%Department of Urology, Shanghai Clinical College, Anhui Medical University, Shanghai 200072, China%Department of Urology, Shanghai Tenth People’s Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China 2025
Online AccessGet full text
ISSN0366-6999
DOI10.1097/CM9.0000000000003311

Cover

More Information
ISSN:0366-6999
DOI:10.1097/CM9.0000000000003311